TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application to the...

Related Keywords

Israel , Russia , China , Singapore , Japan , Brazil , Australia , Tokyo , India , Switzerland , South Korea , Cambridge , Cambridgeshire , United Kingdom , Massachusetts , United States , Saudi Arabia , Canada , Taiwan , Hong Kong , Great Britain , Chuck Triano , Haruo Naito , Jack Cox , Julie Edelman , Tsujim Protofibrils , Nasdaq , Eisai Inc , Youtube , Washington University School Of Medicine , National Institute On , Drug Administration , Facebook , National Institutes Of Health , European Union , Eisai Co Ltd , United Nations Sustainable Development Goals Sdgs , Alzheimer Network Trials Unit , Biogen Inc , Exchange Commission , Investor Relations Department , Prnewswire Eisai Co Ltd , Public Relations Department , Eisai Europe Ltd , Alzheimer Clinical Trial Consortium , Communications Department , Linkedin , Biologics License Application , Fast Track , Mild Cognitive Impairment , Supplemental Biologics License Application , Antithrombotic Medication , Risk Factors , Intracerebral Hemorrhage , Dose Management , Prescribing Informationfor , Clinical Dementia Rating Sum , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Corporate Concept , United Nations Sustainable Development Goals , Important Targets , Disease Modifying Approach , Intj Mol , Accelerated Approval , Japan Available , Early Alzheimer , New England Journal ,